Study of Anti-TREK-1 Autoantibodies as Markers in Adults with Short-Coupled Ventricular Fibrillation and Idiopathic Ventricular Fibrillation

What this Trial Is About

Short-coupled ventricular fibrillation SCVF is a dangerous heart rhythm disorder that can cause sudden cardiac arrest without clear explanation. Researchers are investigating the role of specific autoantibodies, called anti-TREK-1, which may be linked to this condition by affecting a heart potassium channel. This multicenter observational study aims to confirm whether these autoantibodies can be used as diagnostic and prognostic markers in a diverse group of SCVF patients. Participants will undergo repeated plasma tests to detect anti-TREK-1 autoantibodies using a specialized peptid microarray. The study also includes genetic screening for the Dutch DPP6 risk haplotype to explore its relationship with the autoantibodies. Functional and cellular studies using patient-derived heart cells and advanced RNA sequencing will help understand the cellular mechanisms behind SCVF. During the study, participants will have blood samples collected at three different time points over 12 months to measure the presence and changes in anti-TREK-1 autoantibodies. Researchers will assess how these autoantibodies relate to the severity of the disease. The total study duration extends to the end of 2028, with monitoring focused on biomarker variability and disease impact over one year.

Role of Anti-TREK-1 Autoantibodies in SCVF